Rachel Grisham, MD | Authors

Rachel Grisham, MD is section head of Ovarian Cancer and Director of Gynecologic Medical Oncology, at Memorial Sloan Kettering Cancer Center. She is board certified by the American Board of Internal Medicine in Medical Oncology. Dr. Grisham’s research focuses on development of novel therapies and clinical trial design for treatment of recurrent ovarian cancer. She has a particular interest in the development of novel therapeutics for rare tumors, including low grade serous ovarian cancer and granulosa cell tumors. Dr. Grisham is a graduate of the ASCO Leadership Development Program and served as the chair the of Gynecologic Cancer Track of the 2021 ASCO Annual Scientific Meeting. Dr. Grisham has received an ASCO Merit Award, ASCO Conquer Cancer Foundation Career Development Award, Ovarian Cancer Research Fund Alliance Award, Kaleidoscope of Hope Grant, a Cycle for Survival Award, and a Translational and Integrative Medicine Research Fund Grant.


PR-Driven Approaches to Treating Granulosa Cell Tumors

October 16, 2021

Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.